Perspective Therapeutics (CATX) Research & Development (2010 - 2026)
Perspective Therapeutics (CATX) posted Research & Development of $21.4 million for Q1 2026, up 49.12% sequentially from $14.3 million in Q1 2025, and up 49.12% YoY from $14.3 million in Q1 2025.
Perspective Therapeutics (CATX) Research & Development (2010 - 2026) Analysis & Trends
Perspective Therapeutics has reported Research & Development for 17 years, with the latest figure at $21.4 million in Q1 2026.
- Quarterly Research & Development rose 49.12% year-over-year to $21.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $60.6 million (up 24.93% YoY) and the FY2025 annual result came in at $84.2 million, up 102.26% from the prior year.
- Research & Development advanced to $21.4 million in Q1 2026 per CATX's latest filing, from $14.3 million in the prior quarter.
- Over five years, Research & Development peaked at $21.4 million in Q1 2026 and troughed at $468000.0 in Q4 2022.
- A 5-year average of $7.4 million and a median of $6.3 million in 2023 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2023: Research & Development plunged 33.33% in 2022, then soared 1412.82% in 2023.
- Over 5 years, Research & Development stood at $468000.0 in 2022, then jumped by 1412.82% to $7.1 million in 2023, then surged by 81.96% to $12.9 million in 2024, then advanced by 11.25% to $14.3 million in 2025, then soared by 49.12% to $21.4 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $21.4 million, $14.3 million, and $12.9 million for Q1 2026, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 200.08 Bn | 194.48 Bn | 7.27 Bn | 892.00 Mn |
| 2 | Stryker | 129.71 Bn | 126.23 Bn | 4.50 Bn | 434.00 Mn |
| 3 | Medtronic | 120.07 Bn | 110.85 Bn | 6.41 Bn | 671.00 Mn |
| 4 | Boston Scientific | 74.08 Bn | 73.54 Bn | 3.85 Bn | 554.00 Mn |
| 5 | Edwards Lifesciences | 52.68 Bn | 48.43 Bn | 1.35 Bn | 278.90 Mn |
| 6 | Dexcom | 34.51 Bn | 32.56 Bn | 830.00 Mn | 153.00 Mn |
| 7 | GE HealthCare Technologies | 34.03 Bn | 31.92 Bn | 2.18 Bn | 323.00 Mn |
| 8 | Koninklijke Philips | 26.51 Bn | 23.19 Bn | 4.55 Bn | -562.58 Mn |
| 9 | Steris | 23.20 Bn | 22.72 Bn | 684.20 Mn | 28.60 Mn |
| 10 | Perspective Therapeutics | 388.50 Mn | 388.50 Mn | - | 21.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.54 Mn |
| Mar 31, 2026 | 21.37 Mn |
| Mar 31, 2025 | 14.33 Mn |
| Dec 31, 2024 | 12.88 Mn |
| Sep 30, 2024 | 12.03 Mn |
| Jun 30, 2024 | 9.28 Mn |
| Mar 31, 2024 | 7.45 Mn |
| Dec 31, 2023 | 7.08 Mn |
| Sep 30, 2023 | 5.55 Mn |
| Jun 30, 2023 | 5.37 Mn |
| Mar 31, 2023 | 3.31 Mn |
| Dec 31, 2022 | 468,000.00 |
| Sep 30, 2022 | 2.05 Mn |
| Jun 30, 2022 | 1.35 Mn |
| Mar 31, 2022 | 549,000.00 |
| Dec 31, 2021 | 702,000.00 |
| Sep 30, 2021 | 761,000.00 |
| Mar 31, 2021 | 581,000.00 |
| Dec 31, 2020 | 285,000.00 |
| Sep 30, 2020 | 312,000.00 |